The fatty liver disease MASH is one of the metabolic disorders that Nula Therapeutics is pursuing. The startup’s small molecules are intended to restore the integrity of the nuclear envelope, a cellular membrane whose dysfunction can contribute to metabolic disease.
The post Startup Nula Emerges to Advance a New Class Medicines for Metabolic Disease appeared first on MedCity News.
